** Shares of drugmaker Perrigo PRGO.N up 6.78% at $27
** Co reports Q1 adj. profit of $0.60 per share, above analysts' estimate of $0.55 per share, according to data compiled by LSEG
** Also reaffirms all previously provided 2025 financial targets, including adj. EPS range
** Widens 2025 net sales growth target range to 0%-3%, due to macroeconomic uncertainty, vs analysts' estimate of 1.42% growth
** "Maintaining margins and profit guidance is positive, showing management's good visibility into execution benefits. '25 is largely a self-help year" - Jefferies
** Co posts Q1 net sales of $1.04 billion
** As of last close, stock was up ~1.91% YTD
(Reporting by Megha Kumari)
((Megha.Kumari@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。